|Day Low/High||118.56 / 119.74|
|52 Wk Low/High||89.90 / 126.07|
It could well be the stock market, not the Fed, that is driving our retail and services.
Here are 10 stocks hedge fund manager John Paulson has been buying lately, either initiating new stakes or upping his holdings significantly.
Jim Cramer ponders how the playing field is being leveled and how three stocks indicate a change in interest rates.
Its long-term reputation appears to be supporting the shares far more than they deserve.
Preserve capital, and pick up safe income from these blue-chip dividend stocks.
Johnson & Johnson, American Electric Power and Federal Realty say rates are going higher.
Be aware that Johnson & Johnson, American Electric Power and Federal Realty don't roll over idly.
These blue chip stocks have boosted their dividends for at least 40 consecutive years and provide some of the most reliable dividend payments in the market.
FDA action marks second Breakthrough Therapy Designation for intranasal esketamine, highlighting its potential as treatment for patients with major depressive disorder who are at imminent risk for suicide and for those with treatment-resistant depression
Cardinal Health (CAH) offers a compelling dividend investment opportunity. Here's why.
A study of analyst recommendations at the major brokerages shows that Johnson & Johnson is the #14 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Within the broader S&P 500, when components were ranked in terms of analyst favorites, JNJ claims the #289 spot.
Zimmer's return to growth is fueling acquisition thoughts by analysts. There are a number of possibilities.
Zimmer Biomet is on track to return to growth, which could signal more mergers and acquisitions within the industry.
The company's hepatitis C drug division is expected to see losses in the second half of the year.
The net differential for the exchanges caught one off guard.
These 10 dividend aristocrat stocks offer an average high yield of 3% and have increased dividends for 46 consecutive years on average.
A TauRx Therapeutics drug designed to dissolve tangles of a protein called tau in the brain failed to slow cognitive and functional declines of Alzheimer's patients compared with a control.
Cramer is gearing up for the heaviest week of this earnings season, but he's also providing his game plan for helping you be a better investor.
A source familiar with the matter said that TSG Consumer Partners earned 25 times its 2013 minority investment in the makeup company.
There are plenty of doubters about the market and its record highs.
Deutsche Bank upped its price target on Johnson & Johnson (JNJ) stock to $142 from $125 on Thursday morning.
These blue-chip stocks pay safe, generous dividends and form the foundation of a sturdy retirement portfolio.
Valeant could rake in more than $1 billion annually in new sales after FDA approval of a key drug.
This health and drug giant is the best in its class. Here is why investors need to load up on J&J stock, which won't disappoint over the long run.